HK1144580A1 - Crystal structures of neuropilin fragments and neuropilin-antibody complexes - Google Patents

Crystal structures of neuropilin fragments and neuropilin-antibody complexes

Info

Publication number
HK1144580A1
HK1144580A1 HK10111153.8A HK10111153A HK1144580A1 HK 1144580 A1 HK1144580 A1 HK 1144580A1 HK 10111153 A HK10111153 A HK 10111153A HK 1144580 A1 HK1144580 A1 HK 1144580A1
Authority
HK
Hong Kong
Prior art keywords
neuropilin
fragments
crystal structures
antibody complexes
complexes
Prior art date
Application number
HK10111153.8A
Other languages
English (en)
Inventor
Brent A Appleton
Christian Wiesmann
Yan Wu
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of HK1144580A1 publication Critical patent/HK1144580A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cell Biology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Transplantation (AREA)
  • Reproductive Health (AREA)
HK10111153.8A 2007-05-17 2010-11-30 Crystal structures of neuropilin fragments and neuropilin-antibody complexes HK1144580A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2007/069185 WO2008143666A2 (fr) 2007-05-17 2007-05-17 Structures cristallines des fragments de neuropiline et complexes neuropiline-anticorps

Publications (1)

Publication Number Publication Date
HK1144580A1 true HK1144580A1 (en) 2011-02-25

Family

ID=38963109

Family Applications (1)

Application Number Title Priority Date Filing Date
HK10111153.8A HK1144580A1 (en) 2007-05-17 2010-11-30 Crystal structures of neuropilin fragments and neuropilin-antibody complexes

Country Status (14)

Country Link
US (2) US8318163B2 (fr)
EP (1) EP2158215B1 (fr)
JP (1) JP2010530359A (fr)
KR (1) KR101523788B1 (fr)
CN (1) CN101743253B (fr)
AU (1) AU2007353779B2 (fr)
BR (1) BRPI0721707A2 (fr)
CA (1) CA2687556A1 (fr)
ES (1) ES2541051T3 (fr)
HK (1) HK1144580A1 (fr)
IL (1) IL201983A (fr)
MX (1) MX2009012282A (fr)
RU (1) RU2012109383A (fr)
WO (1) WO2008143666A2 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY31800A (es) * 2008-05-05 2009-11-10 Smithkline Beckman Corp Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb
WO2011159980A1 (fr) * 2010-06-18 2011-12-22 Genentech, Inc. Anticorps anti-axl, et procédés d'utilisation.
EP2686020B1 (fr) 2011-03-17 2017-02-22 The University of Birmingham Immunothérapie redirigée
KR102312856B1 (ko) 2012-08-24 2021-10-13 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 Ror1 암을 치료하고 전이를 저해하는데 이용을 위한 항체와 백신
CN103992377B (zh) * 2013-02-18 2017-05-17 上海市第一人民医院 一种抑制新生血管的小肽及其应用
CN103992376B (zh) * 2013-02-18 2017-05-17 上海市第一人民医院 一种抑制新生血管的小肽及其应用
CA2907046C (fr) 2013-03-15 2021-04-20 Atyr Pharma, Inc. Conjugues histidyl-arnt synthetase-region fc
ES2865488T3 (es) * 2014-09-05 2021-10-15 Rsem Lp Composiciones y métodos para el tratamiento y la prevención de la inflamación
WO2017119435A1 (fr) 2016-01-06 2017-07-13 株式会社オーダーメードメディカルリサーチ Anticorps d'une grande affinité avec vegf
WO2017119434A1 (fr) 2016-01-06 2017-07-13 株式会社オーダーメードメディカルリサーチ Anticorps empêchant la liaison vegf - nrp1
CN109996544A (zh) 2016-06-27 2019-07-09 加利福尼亚大学董事会 癌症治疗组合
JOP20190134A1 (ar) * 2016-12-23 2019-06-02 Potenza Therapeutics Inc بروتينات رابطة لمولد ضد مضادة لنيوروبيلين وطرق استخدامها
CA3060514A1 (fr) 2017-04-20 2018-10-25 Atyr Pharma, Inc. Compositions et procedes pour le traitement d'inflammation pulmonaire
WO2018226671A1 (fr) 2017-06-06 2018-12-13 Stcube & Co., Inc. Procédés de traitement du cancer à l'aide d'anticorps et de molécules se liant à btn1a1 ou des ligands de btn1a1
CN113226367A (zh) 2018-04-06 2021-08-06 Atyr 医药公司 包括抗nrp2抗体的组合物和方法
WO2020131697A2 (fr) 2018-12-17 2020-06-25 Revitope Limited Recruteur de cellules immunitaires jumelles
TW202126685A (zh) 2019-09-24 2021-07-16 德商百靈佳殷格翰國際股份有限公司 抗nrp1a抗體及其用於治療眼或眼部疾病之用途
CA3156803A1 (fr) 2019-10-03 2021-04-08 Atyr Pharma, Inc. Compositions et methodes comprenant des anticorps anti-nrp2
GB202207116D0 (en) * 2022-05-16 2022-06-29 Quadram Inst Bioscience Method and Compositions for Tumorigenesis Inhibition
CN114949224B (zh) * 2022-06-06 2023-03-14 山东大学第二医院 Nrp2激动剂在制备复发性流产治疗药物中的应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
CA2345497A1 (fr) 1988-10-28 1990-04-28 Genentech, Inc. Variantes de l'hormones de croissance et procede de fabrication des variantes de l'hormone de croissance
JP2919890B2 (ja) 1988-11-11 1999-07-19 メディカル リサーチ カウンスル 単一ドメインリガンド、そのリガンドからなる受容体、その製造方法、ならびにそのリガンドおよび受容体の使用
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5723286A (en) 1990-06-20 1998-03-03 Affymax Technologies N.V. Peptide library and screening systems
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
DK0564531T3 (da) 1990-12-03 1998-09-28 Genentech Inc Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber
PT100379B (pt) 1991-04-10 1999-01-29 Scripps Research Inst Bibliotecas de receptores heterodimericos usando fagomideos
WO1994004679A1 (fr) 1991-06-14 1994-03-03 Genentech, Inc. Procede pour fabriquer des anticorps humanises
CA2103059C (fr) 1991-06-14 2005-03-22 Paul J. Carter Methode de production d'anticorps humanises
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
DK0666868T4 (da) 1992-10-28 2006-09-18 Genentech Inc Anvendelse af anti-VEGF-antistoffer til behandling af cancer
WO1994013804A1 (fr) 1992-12-04 1994-06-23 Medical Research Council Proteines de liaison multivalentes et multispecifiques, leur fabrication et leur utilisation
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
PT973804E (pt) 1997-04-07 2007-03-30 Genentech Inc Anticorpos anti-vegf
US20050106667A1 (en) * 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences

Also Published As

Publication number Publication date
IL201983A (en) 2015-03-31
CA2687556A1 (fr) 2008-11-27
CN101743253A (zh) 2010-06-16
CN101743253B (zh) 2013-05-08
RU2012109383A (ru) 2013-09-20
ES2541051T3 (es) 2015-07-15
MX2009012282A (es) 2009-11-25
BRPI0721707A2 (pt) 2013-01-15
US8466264B2 (en) 2013-06-18
KR20100020967A (ko) 2010-02-23
US20100150919A1 (en) 2010-06-17
JP2010530359A (ja) 2010-09-09
IL201983A0 (en) 2010-06-16
AU2007353779A1 (en) 2008-11-27
KR101523788B1 (ko) 2015-06-26
WO2008143666A3 (fr) 2009-02-05
EP2158215B1 (fr) 2015-04-22
WO2008143666A2 (fr) 2008-11-27
US8318163B2 (en) 2012-11-27
EP2158215A2 (fr) 2010-03-03
US20120322989A1 (en) 2012-12-20
AU2007353779B2 (en) 2013-11-07

Similar Documents

Publication Publication Date Title
HK1144580A1 (en) Crystal structures of neuropilin fragments and neuropilin-antibody complexes
HRP20160949T1 (hr) Novi sastavi i metode za liječenje karcinoma
IL197315A0 (en) Treatment of cancer
HK1159498A1 (en) Methods and compositions for the treatment of cancer
TWI341406B (en) Diaply panel and its application
EP2234628A4 (fr) Compositions et procédés pour favoriser la guérison d'une plaie
EP2049151A4 (fr) Méthodes et compositions pour le traitement du cancer
EP2340027A4 (fr) Procédés et compositions destinés au traitement du cancer
EP2176406A4 (fr) Compositions et procédés de traitement du cancer
PL2212468T3 (pl) Zastosowanie wielosiarczku w zmodyfikowanym gotowaniu
EP1986682A4 (fr) Procedes et compositions lies au ciblage de tumeurs et de plaies
PL381862A1 (pl) Zastosowanie związków pirydyniowych i sposób leczenia
EP2150270A4 (fr) Méthodes et compositions pour traiter le cancer
IL206189A0 (en) Compound for use in the treatment of cancer
GB2465907B (en) VHZ for diagnosis and treatment of cancer
GB0611136D0 (en) Crystal structure
ZA201001862B (en) Iron-containing composition and the process to prepare such
GB0615934D0 (en) Crystal structure
AU2007297869A8 (en) Crystal structure of CRIg and C3b: CRIg complex
EP2042498A4 (fr) Cristal de derive de benzoxadiazole
GB0716322D0 (en) Crystal structure
IL184620A0 (en) Composition for the treatment of inflammation
GB0600903D0 (en) Treatment of cancer
ZA200810226B (en) Crystal structure of CRIg and C3b; CRIg complex
HK1207370A1 (en) Crystal structures of sglt2 inhibitors and processes for preparing same sglt2

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20170517